ABUS
ABUS clinical trials: Arbutus Biopharma Corp
Every trial on ClinicalTrials.gov where Arbutus Biopharma Corp is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 11
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ABUS on the catalyst calendar · ABUS registry changes
- Primary completion Dec 4, 2025ActualPhase 1NCT05960240Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.Arbutus Biopharma Corporation · Chronic Hepatitis bCompletedABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 13, 2025ActualPhase 2NCT04980482Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionArbutus Biopharma Corporation · Chronic Hepatitis bCompletedABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2029Sponsor estimateNo phase registeredNCT06277037Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)Arbutus Biopharma Corporation · Long Term Follow-upRecruitingABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2024ActualPhase 2NCT06245291Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV InfectionArbutus Biopharma Corporation · Hepatitis B, ChronicWithdrawnABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 17, 2022ActualPhase 1NCT04775797Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV InfectionArbutus Biopharma Corporation · Chronic HepatitisTerminatedABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2016ActualPhase 1/Phase 2NCT02191878Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular CarcinomaArbutus Biopharma Corporation · Hepatocellular CarcinomaCompletedABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2015ActualPhase 1/Phase 2NCT01262235A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) PatientsArbutus Biopharma Corporation · CancerCompletedABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2018ActualPhase 2NCT02631096Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue TherapyArbutus Biopharma Corporation · Hepatitis B, ChronicCompletedABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2015ActualPhase 1NCT02041715Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802Arbutus Biopharma Corporation · Ebola Virus InfectionTerminatedABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2012ActualPhase 1NCT01518881Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 InfusionArbutus Biopharma Corporation · Ebola Virus InfectionTerminatedABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2009ActualPhase 1NCT00927459Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High...Arbutus Biopharma Corporation · HypercholesterolemiaTerminatedABUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT06154278Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis BUniversity of Maryland, Baltimore · Chronic Hepatitis BRecruitingABUSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2023ActualPhase 2NCT04820686A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B InfectionAssembly Biosciences · Chronic Hepatitis BTerminatedASMBLeadABUSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner